Cancer biotech Acceleron Pharma sets terms for $65 million IPO

By
A A A
Share |

Acceleron Pharma, a clinical stage biotech developing protein therapeutics for cancer and rare diseases, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $65 million by offering 4.7 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Acceleron Pharma would command a market value of $370 million.

Acceleron Pharma, which was founded in 2003 and booked $49 million in collaboration and grant revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol XLRN. Acceleron Pharma initially filed confidentially on July 3, 2013. Citi and Leerink Swann are the joint bookrunners on the deal. 



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: XLRN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

74,972,696
  • $16.29 ▲ 1.24%
58,110,176
  • $63.0301 ▲ 2.92%
52,113,540
  • $4.30 ▲ 4.37%
45,053,607
  • $26.18 ▲ 3.40%
40,556,519
  • $3.22 ▲ 0.94%
33,697,770
  • $50.83 ▲ 1.90%
33,642,638
  • $4.56 ▲ 2.01%
31,530,460
  • $20.06 ▲ 11.88%
As of 4/22/2014, 04:07 PM